CJC-1295 + Ipamorelin Blend
Also referenced as: CJC/Ipa, CJC-1295 with Ipamorelin 10/10 mg
A combination research vial pairing a long-acting GHRH analogue with a selective ghrelin receptor agonist, commonly supplied as 10 mg of each.
- Evidence grade
- DPreclinical Research
Preclinical Research
- Regulatory status
- Research Use Only
Neither component is approved for the purposes discussed here, and no approved product combines them. Sold as research-use-only material.
- Human data
- No
No registered clinical trials identified
- Last reviewed
- September 14, 2026
Overview
This blend combines CJC-1295, a growth-hormone-releasing hormone analogue, with ipamorelin, a selective growth hormone secretagogue. Each is covered in its own guide on this site.
The stated rationale is that the two act on different receptors in the growth hormone axis, so combined stimulation may produce a larger pulse than either alone. That rationale comes from separate mechanistic studies, not from trials of the blend.
Commonly supplied for research as a single vial containing 10 mg of each compound. No published trial has evaluated this specific combination in humans.
Why It's Being Studied
- Combined GHRH and ghrelin-receptor stimulation of pulsatile growth hormone release.
- Downstream IGF-1 response as a measurable biomarker.
- Convenience of one reconstituted vial in research settings.
Mechanism of Action
One component tells the pituitary to release growth hormone, the other removes a brake on that release. Together they are proposed to produce a bigger pulse.
CJC-1295 is a modified GHRH(1-29) analogue acting at the GHRH receptor to raise cAMP in somatotrophs. Ipamorelin is a selective GHS-R1a agonist, acting through a phospholipase C pathway and suppressing somatostatin tone. Co-administration of a GHRH analogue and a secretagogue produces synergistic GH release in mechanistic studies of the separate compounds.
Research Areas & Routes Studied
- Growth hormone secretion
- IGF-1 response
- Body composition (claimed, not demonstrated for the blend)
- Subcutaneous injection (research)
Evidence Summary
Each component has separate early human or preclinical data, but the combination itself has not been studied in controlled human trials.
Human clinical evidence
- No controlled human trial of this combination has been identified.
- Separate early human studies of CJC-1295 and ipamorelin report increased GH and IGF-1 concentrations.
Preclinical evidence
- Animal and pituitary-cell work supports synergy between GHRH-receptor and GHS-R1a stimulation.
Anecdotal / community information
- Most information about this blend is community-generated and describes subjective sleep, recovery and body-composition effects.
Reported Adverse Events in Research
- Injection-site reactions, flushing and headache are reported for the individual components.
- Water retention and transient increases in fasting glucose are plausible with sustained GH elevation.
- Combination products carry the adverse-event profile of both components, and blending complicates attribution.
Limitations of Current Evidence
- No trial evidence for the combination, so component data cannot be assumed to transfer.
- Blended vials make it impossible to adjust or attribute effects to one compound.
- Purity and true content of each component in a blended research vial cannot be assumed without a certificate of analysis.
Why It Is Used
- Growth Hormone
Body Composition and Sleep Quality
Growth-hormone secretagogues are used for the same reason across the board: better sleep first, body composition later.
Read the case study - Sleep
Sleep Onset and Sleep Depth
Delta sleep-inducing peptide has the most promising name and some of the thinnest evidence on this site. That contrast is instructive.
Read the case study
Research References
- Phase 1 trial
CJC-1295 pharmacokinetics and GH/IGF-1 response in healthy adults
- Animal study
Ipamorelin: a selective growth hormone secretagogue